Lipid nanoparticles (LNPs)
The non-viral vector for RNA therapies
Advancing gene therapies into clinical trials
Your partner for LNP gene therapies, including personalized therapies
The next wave of gene therapies won’t fail on biology… they’ll stall on developability and manufacturing.
The Gap: No operator covers end-to-end development from screening to the clinic for LNP gene therapies.
CMC Genie is your development partner from concept to clinic — not another CDMO who sells batches.
Our team oversees the complete workflow from screening onward, directly supporting your clinical success.
Founded by senior experts who have taken multiple gene therapy LNPs into the clinic, we offer start-up friendly flexible and modular terms, aligned with a partner’s capital position at each stage of the program.
Leveraging deep expertise across lipid chemistry, formulation, analytical development, technology transfer, QC/QA, and regulatory workflows, our diverse team ensures a seamless transition to the clinic. This is backed by our global network of development labs and GMP-compliant manufacturing facilities.
Through iterative collaboration and rigorous quality assurance, we ensure your molecule remains scalable, robust, and compliant with prevailing standards.